First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.

The New England Journal of Medicine
Alice T ShawCROWN Trial Investigators

Abstract

Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with ALK-positive non-small-cell lung cancer (NSCLC). The efficacy of lorlatinib, as compared with that of crizotinib, as first-line treatment for advanced ALK-positive NSCLC is unclear. We conducted a global, randomized, phase 3 trial comparing lorlatinib with crizotinib in 296 patients with advanced ALK-positive NSCLC who had received no previous systemic treatment for metastatic disease. The primary end point was progression-free survival as assessed by blinded independent central review. Secondary end points included independently assessed objective response and intracranial response. An interim analysis of efficacy was planned after approximately 133 of 177 (75%) expected events of disease progression or death had occurred. The percentage of patients who were alive without disease progression at 12 months was 78% (95% confidence interval [CI], 70 to 84) in the lorlatinib group and 39% (95% CI, 30 to 48) in the crizotinib group (hazard ratio for disease progression or death, 0.28; 95% CI, 0.19 to 0.41; P<0.001). An objective response occurred in 76% (95% CI, 68 to 83) of the patients in the lor...Continue Reading

References

Oct 29, 2010·The New England Journal of Medicine·Eunice L KwakA John Iafrate
Mar 23, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel B CostaKeith D Wilner
Sep 18, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ryohei KatayamaAlice T Shaw
Dec 4, 2014·The New England Journal of Medicine·Benjamin J SolomonUNKNOWN PROFILE 1014 Investigators
Feb 6, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Justin F GainorAlice T Shaw
Jun 2, 2016·American Society of Clinical Oncology Educational Book·Vyshak A Venur, Manmeet S Ahluwalia
Jun 7, 2017·The New England Journal of Medicine·Solange PetersUNKNOWN ALEX Trial Investigators
Oct 4, 2018·The New England Journal of Medicine·D Ross CamidgeSanjay Popat
Mar 21, 2019·The Oncologist·Todd M BauerAlice T Shaw
Mar 21, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alice T ShawJean-François Martini
Mar 25, 2019·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·D Ross CamidgeAlice T Shaw
Aug 26, 2019·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Leora HornChristine M Lovly
Nov 19, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A Drilon
Apr 1, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A Drilon
Aug 12, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D Ross CamidgeSanjay Popat

❮ Previous
Next ❯

Citations

Dec 3, 2020·Nature Reviews. Clinical Oncology·Diana Romero
Jan 13, 2021·Cancer Cell·Shelley Kuang, Natasha B Leighl
Jan 27, 2021·Pharmaceuticals·Mei Elsayed, Petros Christopoulos
Feb 17, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser H HannaGregory Masters
Feb 26, 2021·Nature Communications·Hayato MizutaRyohei Katayama
Feb 28, 2021·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E FelipB Besse
Mar 11, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Shimin XieXiao Zhu
Mar 21, 2021·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T E Stinchcombe
Mar 21, 2021·Cancer Treatment Reviews·Jordi RemonFrancesco Passiglia
Mar 27, 2021·The Lancet. Haematology·Ghulam Rehman MohyuddinVinay Prasad
Mar 31, 2021·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·David Ross Camidge
Mar 31, 2021·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Misako Nagasaka, Sai-Hong Ignatius Ou
May 8, 2021·World Journal of Clinical Oncology·Mathieu ChevallierAlex Friedlaender
May 8, 2021·Frontiers in Oncology·Mei ElsayedPetros Christopoulos
Apr 28, 2021·Expert Review of Anticancer Therapy·Giuseppe BronteLucio Crinò
May 19, 2021·Nature Reviews. Drug Discovery·Philip CohenPasi A Jänne
May 22, 2021·Journal of Pathology and Translational Medicine·Jang-Hee Kim
May 11, 2021·Molecular Oncology·Martyna Filipska, Rafael Rosell
May 28, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicolò Matteo Luca BattistiAlistair Ring
May 1, 2021·Current Opinion in Pulmonary Medicine·Francesco Passiglia, Giorgio V Scagliotti
Jun 3, 2021·Journal of Medicinal Chemistry·Jennifer Alisa AmrheinThomas Hanke
Jun 11, 2021·Current Treatment Options in Oncology·Kazuhiro SaseMikio Mukai
Jun 21, 2021·Critical Reviews in Oncology/hematology·Serena Ceddia, Giovanni Codacci-Pisanelli
Jun 23, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Hou-Qun YingXue-Xin Cheng
Jun 28, 2021·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Shannon S ZhangSai-Hong Ignatius Ou
Jul 10, 2021·Journal of Hematology & Oncology·Umair MajeedYanyan Lou
Jul 19, 2021·European Journal of Drug Metabolism and Pharmacokinetics·Elodie JouanOlivier Fardel

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.